ATMP published and due to take effect by year end
This article was originally published in Clinica
The EU's new Advanced Therapies Medicinal Products (ATMP) Regulation was published in the Official Journal of the European Union on November 13 and will take effect on December 30. The Regulation covers cell therapy, gene therapy and healthcare products containing viable human tissue-engineered products (hTEPs) and non-viable TEPs where the human tissue has a primary (rather than ancillary) action, under the pharmaceutical framework.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.